Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 6/20 | 0.37 |
| ▸ | FAAH | O00519 | 4/20 | 0.35 |
| ▸ | CES2 | O00748 | 2/20 | 0.35 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.35 |
| ▸ | BHMT | Q93088 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL679006 | 0.80 | CES1 (0.39) | CES1FAAHCES2PLA2G6 | |
| SCHEMBL6129960 | 0.77 | CYP2D6 (0.40) | CES1FAAHCES2PLA2G6 | |
| SCHEMBL5277669 | 0.76 | ALDH1A1 (0.39) | HTR1ADRD2HTR2AHTR7CES2 | |
| SCHEMBL9525474 | 0.76 | HTR1A (0.36) | HTR1ADRD2HTR2AHTR7CES2 | |
| SCHEMBL20411535 | 0.76 | CES2 (0.48) | HTR1ADRD2HTR2AHTR7CES2 | |
| SCHEMBL9525485 | 0.76 | CYP2D6 (0.50) | HTR1ADRD2HTR2AHTR7BHMT | |
| Hydrochloric Acid SCHEMBL14157523 | 0.74 | CYP2D6 (0.48) | BHMT | |
| SCHEMBL19731078 | 0.72 | HTT (0.40) | CES1 | |
| SCHEMBL679021 | 0.72 | CES1 (0.47) | CES1FAAHCES2PLA2G6 | |
| SCHEMBL14535086 | 0.72 | CES1 (0.68) | CES1FAAHCES2PLA2G6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895744-B2 | Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2014-11-25 | — | — | US | disclosed |
| US-8895744-B2 | Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2014-11-25 | — | — | US | disclosed |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | ALK, BCR, NPM1 | HTR1A 4128/4885DRD2 2489/4885HTR2A 4375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.